<DOC>
	<DOCNO>NCT00994422</DOCNO>
	<brief_summary>The purpose study compare safety efficacy 0.5 % ivermectin cream placebo subject infest head louse use `` home '' environment .</brief_summary>
	<brief_title>Study Comparing Safety Efficacy 0.5 % Ivermectin Cream Placebo Lice Infested Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ivermectin</mesh_term>
	<criteria>Subject must active head louse infestation define : At least 1 live louse ( adult and/or nymph ) present scalp and/or hair , determine trained evaluator ( exception male head household may selfassess lice free ) . Subject male female . Subject weigh least 15kg ( 33 lb ) . Subject good general health base medical history . Each subject must appropriately sign Informed Consent agreement . A caregiver must sign Informed Consent agreement child old enough . Children specify age administer child 's assent form . The caregiver subject must willing allow household member screen head louse . If household member find active head louse infestation , accord criterion ( ) , must willing able participate study . No one work male per family may exclude evaluation selfassessed lice free come due work schedule . If individual may lice , must come test facility ; otherwise entire household exclude study participation . Subject and/or caregiver must physically able willing apply test article . Subject agree use form louse treatment ( commercial , communityanecdotal , mechanical/manual ) participate study . Following application rinse Study Treatment , subject agree shampoo , wash , rinse hair scalp 24hour posttreatment evaluation complete . Subject agree cut chemically treat hair participate study . Subject agree follow study instruction . Female subject childbearing potential ( include female caregiver even treat ) must willing urine pregnancy test . In event subject judge incapable selftreating , household must caregiver willing apply treatment home . History irritation sensitivity ivermectin cream component , pediculicide hair care product . Presentation treatment site visible skin/scalp condition ( ) attributable head louse infestation , erythema score &gt; 2 , blister , vesicle , opinion investigative personnel sponsor , interfere safety and/or efficacy evaluation . Presentation treatment site eczema atopic dermatitis skin/scalp . Treatment market pediculicide ( Over counter [ OTC ] Prescription ) last 7 day . Any condition illness , opinion investigator , may compromise objective protocol . Is receive treatment , opinion investigator study monitor , may interfere study result . Females ( include caregiver come contact investigational product ) pregnant , nurse planning pregnancy . ( NOTE : female caregiver enrol female childbearing potential must negative urine pregnancy test prior treatment ) . If household pregnant female active case louse , entire household exclude participation . If pregnant household member active infestation , individual must NOT caregiver ( one provide treatment household member ) . Is childbearing potential unwilling use adequate method contraception duration study . Adequate method contraception include : abstinence , vasectomized partner , oral birth control pill , birth control injection patch , Intra Uterine Devices , condom spermicidal jelly diaphragm spermicidal jelly , surgical sterilization . Participation previous investigational drug study within past 30 day . Does understand requirement study participation and/or may likely exhibit poor compliance , opinion investigator . Does know household affiliation household member ( i.e. , stay one household consistently , sleep one place several night another place location ) . Household define live share area space ( example house apartment unit ) .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>PEDICULUS HUMANUS CAPITIS</keyword>
	<keyword>Head Lice</keyword>
</DOC>